Prognostic stratification in DLBCL patients with aberrant MYC gene.
MYC rearrangement
diffuse large B‐cell lymphoma
gene signatures
prognostic stratification
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
received:
18
05
2024
accepted:
31
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
aheadofprint
Résumé
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease characterized by a subset of patients who exhibit treatment resistance and poor prognoses. Genomic assays have been widely employed to identify high-risk individuals characterized by rearrangements in the MYC, BCL2 and BCL6 genes. These patients typically undergo more aggressive therapeutic treatments; however, there remains a significant variation in their treatment outcomes. This study introduces an MYC signature score (MYCSS) derived from gene expression profiles, specifically designed to evaluate MYC overactivation in DLBCL patients. MYCSS was validated across several independent cohorts to assess its ability to stratify patients based on MYC-related genetic and molecular aberrations, enhancing the accuracy of prognostic evaluations compared to conventional MYC biomarkers. Our results indicate that MYCSS significantly refines prognostic accuracy beyond that of conventional MYC biomarkers focused on genetic aberrations. More importantly, we found that nearly 50% of patients identified as high risk by traditional MYC metrics actually share similar survival prospects with those having no MYC aberrations. These patients may benefit from standard GCB-based therapies rather than more aggressive treatments. MYCSS provides a robust signature that identifies high-risk patients, aiding in the precision treatment of DLBCL, and minimizing the potential for overtreatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Prevention and Research Institute of Texas
ID : RR180061
Organisme : Center for Biomedical Informatics and Information Technology
ID : 1R01CA269764
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Major A, Smith SM. DA‐R‐EPOCH vs R‐CHOP in DLBCL: how do we choose? Clin Adv Hematol Oncol. 2021;19(11):698–709.
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, et al. Progression‐free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B‐cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827. https://doi.org/10.1093/annonc/mdy203
He MY, Kridel R. Treatment resistance in diffuse large B‐cell lymphoma. Leukemia. 2021;35(8):2151–2165. https://doi.org/10.1038/s41375‐021‐01285‐3
Miyawaki K, Sugio T. Lymphoma microenvironment in DLBCL and PTCL‐NOS: the key to uncovering heterogeneity and the potential for stratification. J Clin Exp Hematop. 2022;62(3):127–135. https://doi.org/10.3960/jslrt.22027
Susanibar‐Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617–629. https://doi.org/10.1002/ajh.26151
Liu Y, Barta SK. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616. https://doi.org/10.1002/ajh.25460
Nowakowski GS, Czuczman MS. ABC, GCB, and double‐hit diffuse large B‐cell lymphoma: does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book. 2015;35:e449–e457. https://doi.org/10.14694/EdBook_AM.2015.35.e449
Li S, Young KH, Medeiros LJ. Diffuse large B‐cell lymphoma. Pathology. 2018;50(1):74–87. https://doi.org/10.1016/j.pathol.2017.09.006
Cucco F, Barrans S, Sha C, Clipson A, Crouch S, Dobson R, et al. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double‐hit. Leukemia. 2020;34(5):1329–1341. https://doi.org/10.1038/s41375‐019‐0691‐6
Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, et al. Molecular high‐grade B‐cell lymphoma: defining a poor‐risk group that requires different approaches to therapy. J Clin Oncol. 2019;37(3):202–212. https://doi.org/10.1200/JCO.18.01314
Alduaij W, Collinge BJ, Ben‐Neriah S, Jiang A, Hilton LK, Boyle M, et al. Molecular determinants of clinical outcomes in a real‐world diffuse large B‐cell lymphoma population. Blood. 2022;141:2493–2507. https://doi.org/10.1182/blood.2022018248
Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben‐Neriah S, et al. Double‐hit gene expression signature defines a distinct subgroup of germinal center B‐cell‐like diffuse large B‐cell lymphoma. J Clin Oncol. 2019;37(3):190–201. https://doi.org/10.1200/JCO.18.01583
Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, et al. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real‐world study. Blood Adv. 2023;7(24):7459–7470. https://doi.org/10.1182/bloodadvances.2023010402
Xia Y, Zhang X. The spectrum of MYC alterations in diffuse large B‐cell lymphoma. Acta Haematol. 2020;143(6):520–528. https://doi.org/10.1159/000505892
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double‐hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361. https://doi.org/10.1182/blood‐2014‐05‐578963
Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, et al. Targeting MYC activity in double‐hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73. https://doi.org/10.1186/s13045‐019‐0761‐2
Rosenwald A, Bens S, Advani R, Barrans S, Copie‐Bergman C, Elsensohn MH, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B‐cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–3368. https://doi.org/10.1200/JCO.19.00743
de Jonge AV, Roosma TJA, Houtenbos I, Vasmel WLE, van de Hem K, de Boer JP, et al. Diffuse large B‐cell lymphoma with MYC gene rearrangements. Eur J Cancer. 2016;55:140–146. https://doi.org/10.1016/j.ejca.2015.12.001
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–494.e15. https://doi.org/10.1016/j.cell.2017.09.027
Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759–1771. https://doi.org/10.1182/blood.2019003535
Frei E, Visco C, Xu‐Monette ZY, Dirnhofer S, Dybkær K, Orazi A, et al. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B‐cell lymphoma. J Clin Pathol. 2013;66(11):956–961. https://doi.org/10.1136/jclinpath‐2013‐201619
Visco C, Li Y, Xu‐Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B‐cell lymphoma: a report from the international DLBCL rituximab‐CHOP consortium program study. Leukemia. 2012;26(9):2103–2113. https://doi.org/10.1038/leu.2012.83
Dreval K, Cruz M, Liuta N, Mirhosseini HL, Brown C, Morin RD, et al. Revisiting Reddy: a DLBCL do‐over. bioRxiv 2023.
International Non‐Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994. https://doi.org/10.1056/NEJM199309303291402
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression‐based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991–9996. https://doi.org/10.1073/pnas.1732008100
Cheng C, Yan X, Sun F, Li LM. Inferring activity changes of transcription factors by binding association with sorted expression profiles. BMC Bioinform. 2007;8:452. https://doi.org/10.1186/1471‐2105‐8‐452
Zhao Y, Varn FS, Cai G, Xiao F, Amos CI, Cheng C. A P53‐deficiency gene signature predicts recurrence risk of patients with early‐stage lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2018;27(1):86–95. https://doi.org/10.1158/1055‐9965.EPI‐17‐0478
Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–3814. https://doi.org/10.1093/nar/gkg509
Yu F, Quan F, Xu J, Zhang Y, Xie Y, Zhang J, et al. Breast cancer prognosis signature: linking risk stratification to disease subtypes. Brief Bioinform. 2019;20(6):2130–2140. https://doi.org/10.1093/bib/bby073
Nabavizadeh R, Bobrek K, Master VA. Risk stratification for bladder cancer: biomarkers of inflammation and immune activation. Urol Oncol. 2020;38(9):706–712. https://doi.org/10.1016/j.urolonc.2020.04.006
Clifford GM, Alberts CJ. Molecular risk stratification for anal cancer prevention. Clin Infect Dis. 2021;72(12):2164–2166. https://doi.org/10.1093/cid/ciaa399
Ichimasa K, Kudo SE, Miyachi H, Kouyama Y, Misawa M, Mori Y. Risk stratification of T1 colorectal cancer metastasis to lymph nodes: current status and perspective. Gut Liver. 2021;15(6):818–826. https://doi.org/10.5009/gnl20224
Trager MH, Geskin LJ, Samie FH, Liu L. Biomarkers in melanoma and non‐melanoma skin cancer prevention and risk stratification. Exp Dermatol. 2022;31(1):4–12. https://doi.org/10.1111/exd.14114
Heinzel A, Perco P, Mayer G, Oberbauer R, Lukas A, Mayer B. From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action. Front Cell Dev Biol. 2014;2:2. https://doi.org/10.3389/fcell.2014.00037